Latest progress in treatment of chronic hepatitis B with tenofovir disoproxil fumarate

There are 400 million individuals infected with chronic hepatitis B virus( HBV) all over the world. The management of chronic hepatitis B( CHB) has been improved markedly over the last decade,primarily due to the availability of oral nucleoside analogue( NA)therapy. Among the numerous NAs,tenofovir disoproxil fumarate( TDF) stands out for its high therapeutic efficacy,low drug resistance,and wide disease spectrum against several types of chronic CHB that can not be cured with NAs. Thus,TDF has been widely used for clinical treatment of chronic HBV infection. This paper describes the efficacy of TDF in nave and treated patients and analyzes its effect on cirrhosis. Furthermore,the safety of TDF therapy is assessed. It is considered that TDF has low resistance rate and high safety,which provides a first- line drug for CHB treatment.